Cellular senescence enhances adaptive anticancer immunosurveillance.

"Disclosure statement M.S. is shareholder of Senolytic Therapeutics, Life Biosciences, Rejuveron Senescence Therapeutics and Altos Labs, and is advisor of Rejuveron Senescence Therapeutics and Altos Labs. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation."

"I.M. was recipient of a FPI fellowship from the Spanish Ministry of Science (PRE2018-083381). Work in the laboratory of F.P. is supported by a Karolinska Institute Starting Grant, Starting Grant from the Swedish Research Council (2019_02050_3), and by grants from the Harald Jeanssons Foundation, the Loo and Hans Osterman Foundation, and Cancerfonden (21 1637 Pj). Work in the laboratory of M.S. was funded by the IRB and “laCaixa” Foundation, and by grants from the Spanish Ministry of Science co-funded by the European Regional Development Fund (ERDF) (SAF-2017-82613-R, RTC-2017-6123-1), European Research Council (ERC-2014-AdG/669622), Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282), and the AECC (PRYCO211023SERR)."